We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

87 hedge funds and large institutions have $352M invested in Spyre Therapeutics in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more capital invested

Capital invested by funds: $95.8M → $352M (+$256M)

231% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 13

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

24% more funds holding

Funds holding: 70 → 87 (+17)

0.58% more ownership

Funds ownership: 2.83% → 3.41% (+0.58%)

Holders
87
Holders Change
+17
Holders Change %
+24.29%
% of All Funds
1.78%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
25
Increased
43
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$20.6M
2
BBA
Baker Bros. Advisors
New York
+$20.3M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.8M
4
BlackRock
BlackRock
New York
+$9.96M
5
O
OrbiMed
New York
+$8.76M

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$1.27M
2
BCM
Bridgeway Capital Management
Texas
-$534K
3
RWM
Ritholtz Wealth Management
New York
-$381K
4
Renaissance Technologies
Renaissance Technologies
New York
-$347K
5
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
-$327K
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
76
STRS Ohio
Ohio
$44K – – –
AIP
77
Ameritas Investment Partners
Nebraska
$34K +$10.3K +54 +57%
IA
78
IFP Advisors
Florida
$23K -$3.81K -20 -17%
BNP Paribas Financial Markets
79
BNP Paribas Financial Markets
France
$17.9K -$46.9K -246 -76%
QCG
80
Quadrant Capital Group
Ohio
$11K +$8.57K +45 New
DWA
81
Dorsey Wright & Associates
California
$11K +$8.76K +46 New
Osaic Holdings
82
Osaic Holdings
Arizona
$7K – – –
Simplex Trading
83
Simplex Trading
Illinois
$6K +$5.52K +29 +2,900%
BCA
84
Berman Capital Advisors
Georgia
$5K +$4.57K +24 New
Federated Hermes
85
Federated Hermes
Pennsylvania
$3K +$2.86K +15 New
Royal Bank of Canada
86
Royal Bank of Canada
Ontario, Canada
$2K -$571 -3 -23%
Daiwa Securities Group
87
Daiwa Securities Group
Japan
$1K – – –
BCM
88
Bridgeway Capital Management
Texas
– -$534K -4,580 Closed
Jacobs Levy Equity Management
89
Jacobs Levy Equity Management
New Jersey
– -$186K -1,596 Closed
PAWC
90
P.A.W. Capital
Connecticut
– -$182K -1,560 Closed
Susquehanna International Group
91
Susquehanna International Group
Pennsylvania
– -$70K -601 Closed
Commonwealth Equity Services
92
Commonwealth Equity Services
Massachusetts
– -$46K -400 Closed
Victory Capital Management
93
Victory Capital Management
Texas
– -$40K -343 Closed
Ohio Public Employees Retirement System (OPERS)
94
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$2K -15 Closed
MAM
95
Meeder Asset Management
Ohio
– -$1K -9 Closed
1 2 3
4

SYRE Hedge Fund Activity: Q2 2020 in Review

87 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2020, worth a combined $352M — up 267% from $95.8M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SYRE positions and 8 closed out — a net gain of 17 holders — while 43 added to existing stakes and 13 trimmed.

The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $20.6M. The largest seller was Soleus Capital Management, cutting an estimated $1.27M.

  • 87 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2020, up from 70 in Q1 2020.
  • Funds reported $352M of Spyre Therapeutics stock for Q2 2020, up 267% quarter-over-quarter.
  • 25 funds opened new Spyre Therapeutics positions in Q2 2020 and 8 closed out, a net change of +17 holders.
  • The largest Spyre Therapeutics buyer in Q2 2020 was Bain Capital Life Sciences Investors, an estimated $20.6M added.
  • The largest Spyre Therapeutics seller in Q2 2020 was Soleus Capital Management, an estimated $1.27M sold.

Based on aggregated 13F filings for Q2 2020.